We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

21 hedge funds and large institutions have $1.3M invested in Theriva Biologics in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

0.04% less ownership

Funds ownership: 0.09% → 0.05% (-0.04%)

9% less funds holding

Funds holding: 23 → 21 (-2)

19% less capital invested

Capital invested by funds: $1.61M → $1.3M (-$313K)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
21
Holders Change
-2
Holders Change %
-8.7%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
2
Closed
6
Calls
$3.55M
Puts
–
Net Calls
+$3.55M
Net Calls Change
+$622K

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$54.2K
2
Renaissance Technologies
Renaissance Technologies
New York
+$33.8K
3
TSS
Two Sigma Securities
New York
+$12.4K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$10.8K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$8.12K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$312K
2
SM
Sabby Management
Florida
-$287K
3
AFM
Anson Funds Management
Texas
-$88K
4
UBS Group
UBS Group
Switzerland
-$13.1K
5
Two Sigma Investments
Two Sigma Investments
New York
-$6K

TOVX Hedge Fund Activity: Q1 2019 in Review

21 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2019, worth a combined $1.3M — down 19% from $1.61M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of TOVX and 4 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 6 added.

The largest buyer was Virtu Financial, adding an estimated $54.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $312K sold.

  • 21 institutional investors held Theriva Biologics (TOVX) as of Q1 2019, down from 23 in Q4 2018.
  • Funds reported $1.3M of Theriva Biologics stock for Q1 2019, down 19% quarter-over-quarter.
  • 4 funds opened new Theriva Biologics positions in Q1 2019 and 6 closed out, a net change of -2 holders.
  • The largest Theriva Biologics buyer in Q1 2019 was Virtu Financial, an estimated $54.2K added.
  • The largest Theriva Biologics seller in Q1 2019 was Armistice Capital, an estimated $312K sold.

Based on aggregated 13F filings for Q1 2019.